Compare · LLY vs PTIX
LLY vs PTIX
Side-by-side comparison of Eli Lilly and Company (LLY) and Protagenic Therapeutics Inc. (PTIX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and PTIX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.11T, about 59651.3x PTIX ($18.7M).
- Over the past year, LLY is up 63.2% and PTIX is down 82.5% - LLY leads by 145.6 points.
- LLY has hit the wire 11 times in the past 4 weeks while PTIX has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 1 for PTIX).
- Company
- Eli Lilly and Company
- Protagenic Therapeutics Inc.
- Price
- $1183.99+0.04%
- $0.73-44.06%
- Market cap
- $1.11T
- $18.7M
- 1M return
- -0.45%
- +0.00%
- 1Y return
- +63.15%
- -82.49%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 1
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Protagenic Therapeutics Inc.
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.
Latest LLY
- FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
- U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,957 units (SEC Form 4)
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,012 units (SEC Form 4)
- Director Alvarez Ralph was granted 11 shares, increasing direct ownership by 0.02% to 55,838 units (SEC Form 4)
- Director Fyrwald J Erik was granted 9 shares, increasing direct ownership by 0.01% to 75,536 units (SEC Form 4)
- U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
- Eli Lilly upgraded by Berenberg with a new price target
- Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
- EVP, Global Quality Seymour Melissa gifted 29 shares, decreasing direct ownership by 3% to 1,038 units (SEC Form 4)
Latest PTIX
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $13,000 worth of shares (20,000 units at $0.65), increasing direct ownership by 37% to 73,533 units (SEC Form 4)
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $9,811 worth of shares (16,634 units at $0.59), increasing direct ownership by 45% to 53,533 units (SEC Form 4)
- Protagenic Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $945 worth of shares (2,700 units at $0.35), increasing direct ownership by 8% to 36,899 units (SEC Form 4)
- Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder
- SEC Form 10-Q filed by Protagenic Therapeutics Inc.
- SEC Form NT 10-Q filed by Protagenic Therapeutics Inc.
- SEC Form 10-K filed by Protagenic Therapeutics Inc.
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $710 worth of shares (2,220 units at $0.32), increasing direct ownership by 7% to 34,199 units (SEC Form 4)
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $151 worth of shares (685 units at $0.22), increasing direct ownership by 2% to 31,979 units (SEC Form 4)